One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The complex relationship among heart failure, cancer, and lipid lowering, and an update on cardiomyopathies
Filippo Crea
doi : 10.1093/eurheartj/ehab554
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3029–3032
Mark Nicholls speaks to Professor Eric Durand and Professor Rémi Sabatier about Europe’s first remote robotic-assisted angioplasty procedure
Mark Nicholls
doi : 10.1093/eurheartj/ehab085
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3033–3035
Syrian Cardiovascular Association: Small Steps towards a Bright Horizon
Amr Abdin, MD, FESC, FHFA, Asim Katbeh, MD, PhD, FESC and Yassin Bani Marjeh, MD
doi : 10.1093/eurheartj/ehab126
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3035–3037
Herbal medicine in cardiovascular medicine: a discussion of herbal medications described by the Persian physician, Avicenna
Bahareh Sadat Yousefsani, Amirhossein Jamshidi, Majid Dadmehr
doi : 10.1093/eurheartj/ehab053
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3037–3039
How a new drug is born
Andrea Caporali, Steven Fawell, Maurizio Scaltriti
doi : 10.1093/eurheartj/ehab076
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3039–3041
A SPRINT towards tighter control of blood pressure in hypertension
Massimo Volpe, Carlo Patrono
doi : 10.1093/eurheartj/ehab400
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3042–3043
The tobacco endgame—eradicating a worsening epidemic: A Joint Opinion From the American College of Cardiology, American Heart Association, European Society of Cardiology, and the World Heart Federation
Jeffrey Willett, Stephan Achenbach, Fausto J Pinto, Athena Poppas, Mitchell S V Elkind
doi : 10.1093/eurheartj/ehab245
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3044–3048
Statin associated lower cancer risk and related mortality in patients with heart failure
Qing-Wen Ren, Si-Yeung Yu, Tiew-Hwa Katherine Teng, Xue Li, Ka-Shing Cheung, Mei-Zhen Wu, Hang-Long Li, Pui-Fai Wong, Hung-Fat Tse, Carolyn S P Lam, Kai-Hang Yiu
doi : 10.1093/eurheartj/ehab325
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3049–3059
Patients with heart failure (HF) have an increased risk of incident cancer. Data relating to the association of statin use with cancer risk and cancer-related mortality among patients with HF are sparse.
Decoding the link between heart failure and incident cancer
Sanjay Divakaran, Anju Nohria
doi : 10.1093/eurheartj/ehab482
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3060–3062
Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy
Luis R Lopes, Soledad Garcia-Hern?ndez, Massimiliano Lorenzini, Marta Futema, Olga Chumakova, Dmitry Zateyshchikov, Maria Isidoro-Garcia, Eduardo Villacorta, Luis Escobar-Lopez, Pablo Garcia-Pavia, Raquel Bilbao, David Dobarro, Maria Sandin-Fuentes, Claudio Catalli, Blanca Gener Querol, Ainhoa Mezcua, Jose Garcia Pinilla, Torsten Bloch Rasmussen, Ana Ferreira-Aguar, Pablo Revilla-Mart?, Maria Teresa Basurte Elorz, Alicia Bautista Paves, Juan Ramon Gimeno, Ana Virginia Figueroa, Raul Franco-Gutierrez, Maria Eugenia Fuentes-Ca?amero, Marina Martinez Moreno, Martin Ortiz-Genga, Jesus Piqueras-Flores, Karina Analia Ramos, Ainars Rudzitis, Luis Ruiz-Guerrero, Ricardo Stein, Mayte Triguero-Bochar?n, Luis de la Higuera, Juan Pablo Ochoa, Dad Abu-Bonsrah, Cecilia Y T Kwok, Jacob B Smith, Enzo R Porrello, Mohammed M Akhtar, Joanna Jager, Michael Ashworth, Petros Syrris, David A Elliott, Lorenzo Monserrat, Perry M Elliott
doi : 10.1093/eurheartj/ehab424
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3063–3073
The aim of this study was to determine the frequency of heterozygous truncating ALPK3 variants (ALPK3tv) in patients with hypertrophic cardiomyopathy (HCM) and confirm their pathogenicity using burden testing in independent cohorts and family co-segregation studies.
ALPK3: a full spectrum cardiomyopathy gene?
Roddy Walsh, Connie R Bezzina
doi : 10.1093/eurheartj/ehab415
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3074–3077
PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction
Lorenzo Da Dalt, Laura Castiglioni, Andrea Baragetti, Matteo Audano, Monika Svecla, Fabrizia Bonacina, Silvia Pedretti, Patrizia Uboldi, Patrizia Benzoni, Federica Giannetti, Andrea Barbuti, Fabio Pellegatta, Serena Indino, Elena Donetti, Luigi Sironi, Nico Mitro, Alberico Luigi Catapano, Giuseppe Danilo Norata
doi : 10.1093/eurheartj/ehab431
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3078–3090
PCSK9 is secreted into the circulation, mainly by the liver, and interacts with low-density lipoprotein receptor (LDLR) homologous and non-homologous receptors, including CD36, thus favouring their intracellular degradation. As PCSK9 deficiency increases the expression of lipids and lipoprotein receptors, thus contributing to cellular lipid accumulation, we investigated whether this could affect heart metabolism and function.
Heart to heart with PCSK9
Kevin Chemello, Ali K Jaafar, Gilles Lambert
doi : 10.1093/eurheartj/ehab480
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3091–3093
Peripartum cardiomyopathy: from genetics to management
Karen Sliwa, Johann Bauersachs, Zolt Arany, Timothy F Spracklen, Denise Hilfiker-Kleiner
doi : 10.1093/eurheartj/ehab458
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3094–3102
Peripartum cardiomyopathy (PPCM) is a disease that occurs globally in all ethnic groups and should be suspected in any peripartum women presenting with symptoms and signs of heart failure, towards the end of pregnancy or in the months following delivery, with confirmed left ventricular dysfunction. After good history taking, all women should be thoroughly assessed, and alternative causes should be excluded. Urgent cardiac investigations with electrocardiogram and natriuretic peptide measurement (if available) should be performed. Echocardiography follows as the next step in investigation. Patients with abnormal cardiac investigations should be urgently referred to a cardiology team for expert management. Referral for genetic work-up should be considered if there is a family history of cardiomyopathy or sudden death. PPCM is a disease with substantial maternal and neonatal morbidity and mortality. Maternal mortality rates range widely, from 0% to 30%, depending on the ethnic background and geographic region. Just under half of women experience myocardial recovery. Remarkable advances in the comprehension of the pathogenesis and in patient management and therapy have been achieved, largely due to team efforts and close collaboration between basic scientists, cardiologists, intensive care specialists, and obstetricians. This review summarizes current knowledge of PPCM genetics, pathophysiology, diagnostic approach, management, and outcome.
Congestive pulmonary oedema during venoarterial extracorporeal membrane oxygenation support: a plea for balloon atrial septostomy
Martin Kloeckner, Julien Guihaire, Sebastien Hascoet
doi : 10.1093/eurheartj/ehab118
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3103–3104
The lack of evidence-based therapeutic strategies for left ventricular unloading during venoarterial extracorporeal membrane oxygenation therapy calls for randomized trials
Enzo Lüsebrink, Steffen Massberg, Martin Orban
doi : 10.1093/eurheartj/ehab120
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3105–3106
Left ventricular pseudoaneurysm as source of recurrent stroke
Kathleen A Young, Crystal R Bonnichsen
doi : 10.1093/eurheartj/ehab040
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Page 3106
Is abnormal function with troponin T elevation definitely myocardial infarction?
Yunli Xing, Ning Dai, Hongwei Li
doi : 10.1093/eurheartj/ehab023
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Page 3107
Late-onset endocarditis after coronavirus disease 2019 infection
Tadao Aikawa, Jiro Ogino, Tamaki Kudo, Yusuke Kashiwagi
doi : 10.1093/eurheartj/ehab065
European Heart Journal, Volume 42, Issue 32, 21 August 2021, Page 3108
